Viral Hepatitis

You have full text access to this OnlineOpen article

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus†

  1. Norman M. Kneteman1,2,‡,§,*,
  2. Anita Y. M. Howe3,
  3. Tiejun Gao1,
  4. Jamie Lewis2,
  5. Dan Pevear4,
  6. Gary Lund1,
  7. Donna Douglas2,
  8. David F. Mercer1,2,
  9. D. Lorne J. Tyrrell1,2,
  10. Frederick Immermann3,
  11. Inder Chaudhary3,
  12. John Speth3,
  13. Stephen A. Villano4,
  14. John O'Connell3,
  15. Marc Collett4

Article first published online: 5 NOV 2008

DOI: 10.1002/hep.22717

Issue

Hepatology

Hepatology

Volume 49, Issue 3, pages 745–752, March 2009

Additional Information

How to Cite

Kneteman, N. M., Howe, A. Y. M., Gao, T., Lewis, J., Pevear, D., Lund, G., Douglas, D., Mercer, D. F., Tyrrell, D. L. J., Immermann, F., Chaudhary, I., Speth, J., Villano, S. A., O'Connell, J. and Collett, M. (2009), HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology, 49: 745–752. doi: 10.1002/hep.22717

Author Information

  1. 1

    KMT Hepatech, Inc., Edmonton, Alberta, Canada

  2. 2

    University of Alberta, Edmonton, Alberta, Canada

  3. 3

    Wyeth Research, Monmouth Junction, NJ

  4. 4

    Viropharma, Inc., Exton, PA

  1. ‡

    These authors contributed equally.

  2. §

    fax: 780-407-7374

*Department of Surgery, University of Alberta Hospital, 2D4.44 Walter Mackenzie Centre, Edmonton, Alberta T6G 2B7, University of Alberta, Surgery, Edmonton, Alberta, Canada

  1. †

    Potential conflict of interest: Drs. Kneteman, Mercer, and Lund own stock in KMT Hepatech, Inc. Dr. Immermann owns stock in Wyeth Research. Dr. Villano owns stock in Viropharma, Inc. Dr. Collett owns stock in Wyeth Research and Viropharma.

  2. ‡

    These authors contributed equally.

  3. §

    fax: 780-407-7374

Publication History

  1. Issue published online: 24 FEB 2009
  2. Article first published online: 5 NOV 2008
  3. Accepted manuscript online: 5 NOV 2008 12:00AM EST
  4. Manuscript Accepted: 16 OCT 2008
  5. Manuscript Received: 22 FEB 2008

Funded by

  • Canadian Institutes for Health Research/Wyeth Canada Chair in Transplantation Research and was a Senior Scholar of the Alberta Heritage Foundation for Medical Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (248K)

References

  • 1
    Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, J Viral Hepatol 1999; 6: 35–47.
    Direct Link:
  • 2
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.
  • 3
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899–1905.
  • 4
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 Gastroenterology 2002; 123: 2082–2099.
  • 5
    Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117: 344–352.
  • 6
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a complementary DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362.
  • 7
    Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997; 71: 8416–8428.
  • 8
    Tomei L, Vitale RL, Incitti I, Serafini S, Altamura S, Vitelli A, et al. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol 2000; 81: 759–767.
  • 9
    Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999; 73: 1649–1654.
  • 10
    Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937–943.
  • 11
    O'Farrell D, Trowbridge R, Rowlands D, Jager J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol 2003; 326: 1025–1035.
  • 12
    Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005; 280: 18202–18210.
  • 13
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.
  • 14
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972–1974.
  • 15
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927–933.
  • 16
    Walker CM. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 1997; 19: 85–98.
  • 17
    Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. HEPATOLOGY 2006; 43: 1346–1353.
    Direct Link:
  • 18
    Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, et al. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2004; 48: 4813–4821.
  • 19
    Howe A, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother. 2008; 52: 3327–3338.
  • 20
    Chandra P RD, Moyer L, Harper D, et al. Safety and pharmacokinetics of the non-nucleoside polymerase inhibitor, HCV-796: results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects. European Association for the Study of Liver (EASL) 2006.
  • 21
    Villano S, Howe A, Raible D, Harper D, Speth J, Bichier G, et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients [Abstract]. HEPATOLOGY 2006; 44( Suppl 1): 607A–608A.
  • 22
    Villano SA, Raible D, Harper D, Speth J, Chandra P, Shaw P, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV. J Hepatol 2007; 46( Suppl 1): S24.
  • 23
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 7271–7276.
  • 24
    Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005; 79: 592–596.
  • 25
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791–796.
  • 26
    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294–9299.
  • 27
    Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623–626.
  • 28
    Shindo M, Di Bisceglie AM, Biswas R, Mihalik K, Feinstone SM.. Hepatitis C virus replication during acute infection in the chimpanzee. J Infect Dis 1992; 166: 424–427.
  • 29
    Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, et al. Hepatitis C virus viremia in SCID–>BNX mouse chimera. J Infect Dis 1995; 172: 25–30.
  • 30
    Xie ZC, Riezu-Boj JI, Lasarte JJ, Guillen J, Su JH, Civeira MP, et al. Transmission of hepatitis C virus infection to tree shrews. Virology 1998; 244: 513–520.
  • 31
    Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447–456.
  • 32
    Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994; 263: 1149–1152.
  • 33
    Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995; 92: 4942–4946.
  • 34
    Gopalsamy A, Lim K, Ciszewski G, Park K, Ellingboe JW, Bloom J, et al. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem 2004; 47: 6603–6608.
  • 35
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186–189.
  • 36
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral activity of interferon alpha therapy. Science 1998; 282: 103–107.
  • 37
    Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186: 146–151.
  • 38
    Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3–4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006; 50: 1813–1822.
  • 39
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270–1278.
View Full Article with Supporting Information (HTML) Get PDF (248K)